TABLE 1.
Metabolites affected by LPS administration in the mouse brains.
| Compound | Control | Abca7± | Ionization mode | MS1 composite spectrum (m/z) | ||
| FC | p-value | FC | p-value | |||
| C24 H9 N11 O4 | −1229.987 | 1.74E–04 | −556.729 | 2.24E–04 | HILIC+ | (516.0915, 2651.58) (517.0916, 692.18) |
| Quinacetol | 703.429 | 1.30E–03 | 144.123 | 1.90E–02 | HILIC+ | (188.0709, 1615.56) (205.0975, 1986.9) (206.1013, 176.11) |
| C21 H43 N4 O4 | 138.129 | 9.79E–03 | 687.350 | 5.39E–04 | HILIC+ | (416.3347, 4091.88) (417.3392, 1173.53) (433.3659, 204.09) |
| His Ala | 2.108 | 8.07E–04 | 1.985 | 2.00E–03 | HILIC+ | (249.0964, 555.13) (227.1139, 44894.72) (228.1171, 4758.09) (229.119, 466.04) |
| Carnosine | 2.012 | 1.70E–04 | 1.753 | 2.79E–04 | HILIC− | (225.0992, 13183.61) (226.1022, 1362.8) |
| PE [15:1(9Z)/22:0] | −4.176 | 2.91E–03 | −2.244 | N.S. | C18+ | (760.5844, 113759.48) (761.5878, 50487.69) |
| POV-PC Esi + 12.015995 | −3.239 | 1.15E–03 | −1.130 | N.S. | C18+ | (616.3578, 50059.41) (617.3611, 15758.59) (594.3764, 170028.23) (595.3793, 52255.38) (596.3819, 11953.29) (597.3852, 1868.63) (611.4076, 297.2) |
| C34 H55 N12 O3 | −2.491 | 2.13E–04 | −1.067 | N.S. | C18+ | (702.4314, 4643.8) (703.4354, 1840.41) (680.4592, 6949.51) (681.4605, 3260.07) (682.4631, 882.31) |
| C32 H51 O10 Esi + 12.411007 | −2.027 | 1.73E–03 | −1.121 | N.S. | C18+ | (618.3381, 4348.9) (619.3419, 1693.53) (596.3551, 18953.5) (597.3587, 6100.73) (598.3611, 1816.91) (599.3599, 222.98) |
| C31 H49 O9 | −2.004 | 3.21E–03 | −1.100 | N.S. | C18+ | (588.3267, 17685.77) (589.3303, 5836.98) (590.3389, 1836.92) (1153.6628, 1279.33) (1154.6656, 840.86) (566.3452, 135593.83) (567.3482, 40496.61) (568.3516, 8898.48) (569.3551, 1504.54) (1131.6823, 1156.18) (1132.6847, 661.48) |
| PE [22:6(4Z,7Z,10Z,13Z, 16Z,19Z)/0:0] Esi + 10.902 | −8.687 | 4.61E–03 | 1.258 | N.S. | C18+ | (548.2743, 95660.68) (549.2773, 29194.23) (526.2926, 565743.44) (527.2959, 167649.31) (528.2982, 29241.65) |
| PE [22:6(4Z,7Z, 10Z,13Z,16Z,19Z)/0:0] | −8.597 | 4.81E–03 | 1.258 | N.S. | C18+ | (548.2743, 95660.68) (549.2773, 29194.23) (526.2926, 565743.44) (527.2959, 167649.31) (528.2982, 29241.65) |
| C20 H16 N O6 | −2.765 | 9.37E–04 | 1.059 | N.S. | HILIC− | (365.0906, 6087.18) (366.094, 981.33) |
| PC [18:3(6Z,9Z,12Z)/ 20:4(8Z,11Z,14Z,17Z)] | 139.405 | 2.04E–02 | −13.074 | N.S. | HILIC+ | (826.5427, 424.52) (804.552, 2422.12) (805.556, 1161.39) |
| PE [19:0/22:6(4Z,7Z, 10Z,13Z,16Z,19Z)] | 2.840 | 1.86E–03 | −1.052 | N.S. | C18+ | (828.5514, 124966.67) (829.5544, 61987.04) (830.5574, 16763.68) (831.5606, 3728.36) |
| Barbituric acid, 5-ethyl-5-(2-hydroxyethyl)- | 2.247 | 1.87E–03 | −1.127 | N.S. | HILIC+ | (223.069, 7991.25) (224.0709, 1855.2) (201.0871, 12020.45) (202.091, 1167.57) |
| PC [17:1(9Z)/ 20:5(5Z,8Z,11Z,14Z,17Z)] | 2.245 | 3.26E–03 | −1.191 | N.S. | C18+ | (814.5356, 84342.96) (815.5387, 42522.77) (816.542, 11650.13) (817.5466, 2508.01) (1606.0784, 4863.3) (1607.0813, 5175.72) (1608.085, 2997.93) (1609.0872, 1133.71) (1610.0887, 307.46) (792.5542, 853601.8) (793.5578, 419070.66) (794.5605, 109935.91) (795.5629, 21364.05) (796.5681, 3906.1) (797.5746, 744.92) (1584.097, 9308.74) (1585.1006, 9151.15) (1586.1033, 4983.11) (1587.1051, 2043.59) (1588.1064, 571.09) |
| PC [18:3(9Z,12Z,15Z)/22:4 (7Z,10Z,13Z,16Z)] | 2.149 | 1.91E–03 | −1.043 | N.S. | C18+ | (854.5667, 23313.19) (855.5701, 12648.29) (856.5735, 3862.51) (857.578, 946.06) (832.5849, 101901.32) (833.5881, 51366.33) (834.5911, 15361.98) (835.5943, 3344.88) (836.6016, 790.0) |
| Ancitabine Esi + 3.470998 | 543.089 | 1.69E–04 | 6.087 | N.S. | HILIC+ | (226.0825, 5276.52) (227.0869, 802.4) |
| Anibine | 286.991 | 2.55E–03 | 2.066 | N.S. | HILIC+ | (226.045, 2249.78) (227.0482, 103.85) (429.0144, 412.48) (204.0632, 922.09) |
| C24 H19 N19 O4 | 110.749 | 5.77E–03 | 4.714 | N.S. | HILIC− | (636.1795, 2567.15) (637.1818, 682.69) |
| C25 H13 N6 O3 | 76.653 | 1.47E–02 | 2.014 | N.S. | HILIC− | (444.0975, 2311.36) (445.1024, 561.37) |
| PC [22:6(4Z,7Z,10Z,13Z,16Z,19Z)/ 22:6(4Z,7Z,10Z,13Z,16Z,19Z)] | 2.530 | 4.69E–04 | 1.157 | N.S. | C18+ | (900.5547, 1268.98) (901.551, 921.35) (902.5487, 329.27) (878.5694, 15051.85) (879.5725, 8619.16) (880.5738, 3269.69) (881.5759, 1019.28) |
| PE [22:6(4Z,7Z,10Z,13Z,16Z,19Z)/ 22:4(7Z,10Z,13Z,16Z)] | 2.206 | 5.36E–04 | 1.106 | N.S. | C18+ | (862.5356, 3496.06) (863.5376, 1840.5) (864.5534, 666.24) (840.5538, 14033.28) (841.5571, 7698.2) (842.5743, 3260.31) |
| PE [22:6(4Z,7Z,10Z,13Z,16Z,19Z)/ 22:6(4Z,7Z,10Z,13Z,16Z,19Z)] | 2.503 | 6.34E–04 | 1.140 | N.S. | C18+ | (858.5046, 3908.22) (859.5076, 2355.39) (860.5147, 904.48) (861.513, 153.03) (836.5229, 15859.57) (837.5261, 8592.62) (838.5362, 4116.88) (839.5368, 919.5) |
| Quercetin 3,4′-dimethyl ether 7-glucoside | 2.100 | 2.90E–03 | 1.303 | N.S. | HILIC− | (491.1188, 9107.03) (492.1217, 2024.41) |
| C6 H10 N2 Esi + 3.0780017 | −1.620 | N.S. | −2.267 | 7.90E–03 | C18+ | (111.0915, 9416.54) (112.0944, 670.02) |
| C33 H39 N14 O | −2.807 | N.S. | −1.585 | 1.09E–02 | C18+ | (670.3348, 81.0) (648.3504, 17316.61) (649.3547, 6659.75) (665.3842, 919.13) |
| C15 H39 N16 | 28.361 | N.S. | 598.849 | 2.73E–04 | HILIC+ | (444.3576, 4252.18) (445.3726, 746.13) (446.3756, 96.88) |
| C18 H39 N9 | −1.073 | N.S. | 3.925 | 9.48E–04 | HILIC+ | (785.6224, 602.19) (382.3266, 5576.34) (383.3276, 2716.83) (399.3647, 8642.28) (400.3722, 2169.87) (780.6662, 3471.65) (781.6672, 1776.56) (764.6397, 5252.95) |
| Docusate | 1.553 | N.S. | 3.088 | 1.69E–04 | HILIC− | (421.2257, 12808.72) (422.2282, 3206.75) (423.2247, 955.26) |
Metabolic signatures with raw p-value ≤ 0.05 and fold change (FC) > 2.0 or <−2.0 induced by LPS administration in control and/or Abca7± mice are listed (N = 6/each). N.S., not significant.